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Cost-Effectiveness of Complementary Therapies in the
United Kingdom—A Systematic Review†
Peter H. Canter, Joanna Thompson Coon and Edzard Ernst
Complementary Medicine, Peninsula Medical School, Exeter Devon EX2 4NT, UK
Objectives: The aim of this review is to systematically summarize and assess all prospective, controlled,
cost-effectiveness studies of complementary therapies carried out in the UK. Data sources: Medline (via
PubMed), Embase, CINAHL, Amed (Alternative and Allied Medicine Database, British Library
Medical Information Centre), The Cochrane Library, National Health Service Economic Evaluation
Database (via Cochrane) and Health Technology Assessments up to October 2005. Review methods:
Articles describing prospective, controlled, cost-effectiveness studies of any type of complementary
therapy for any medical condition carried out in the UK were included. Data extracted included the main
outcomes for health benefit and cost. These data were extracted independently by two authors, described
narratively and also presented as a table. Results: Six cost-effectiveness studies of complementary
medicine in the UK were identified: four different types of spinal manipulation for back pain, one type of
acupuncture for chronic headache and one type of acupuncture for chronic back pain. Four of the six
studies compared the complementary therapy with usual conventional treatment in pragmatic,
randomized clinical trials without sham or placebo arms. Main outcome measures of effectiveness
favored the complementary therapies but in the case of spinal manipulation (four studies) and
acupuncture (one study) for back pain, effect sizes were small and of uncertain clinical relevance. The
same four studies included a cost-utility analyses in which the incremental cost per quality adjusted life
year (QALY) was less than £10 000. The complementary therapy represented an additional health care
cost in five of the six studies. Conclusions: Prospective, controlled, cost-effectiveness studies of
complementary therapies have been carried out in the UK only for spinal manipulation (four studies) and
acupuncture (two studies). The limited data available indicate that the use of these therapies usually
represents an additional cost to conventional treatment. Estimates of the incremental cost of achieving
improvements in quality of life compare favorably with other treatments approved for use in the
National Health Service. Because the specific efficacy of the complementary therapies for these
indications remains uncertain, and the studies did not include sham controls, the estimates obtained may
represent the cost-effectiveness non-specific effects associated with the complementary therapies.
Keywords: complementary medicine – cost effectiveness – acupuncture – spinal manipulation
Introduction
†This review was previously published as a BMJ short report
(1). Here, it is reported in full and has been updated to include
studies published up to October 2005.
Despite the fact that the evidence for effectiveness of
many complementary therapies remains weak, the increased
popularity of privately purchased complementary therapies
in the UK and the ongoing debate about provision and
integration of complementary medicine within the National
Health Service (NHS) has inevitably brought the issue of
cost-effectiveness to the fore. The cost-effectiveness of any
particular treatment depends not only upon the treatments with
which it is compared, but also the health care system in which
it is provided. A treatment which is cost-effective in the health
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care system of one country may not be so in another. We have,
therefore, carried out a systematic review of the most rigorous
studies in order to properly appraise what is currently known
about cost-effectiveness of any complementary therapies in the
UK system.
A full economic evaluation of a health care strategy involves
a comparative analysis of relevant alternative courses of action
in terms of both their costs and consequences. This systematic
review includes only studies evaluating both costs and
consequences of two or more treatment options and therefore
excludes cost-minimization studies which assume equal
effectiveness between interventions and measure only costs.
We justify the exclusion of such studies on the grounds that the
effectiveness of any complementary therapy relative to
conventional treatments remains insufficiently proven. Terms
used to describe different types of economic analyses of health
care strategies are sometimes used inconsistently, but we
follow the terminology outlined by Drummond (2).
Cost-utility analyses frequently estimate cost-effectiveness
using the measure cost per quality adjusted life year (QALY)
gained. One QALY is a year in perfect health and suboptimal
health states are assigned a QALY value between 0 and ±1
following a weighting exercise of some kind which may
include questionnaires, focus groups or expert opinions.
Dimensionally, QALY is a product of incremental gain in
quality of life and the length of time over which the gain in
quality of life is enjoyed. Increasingly, QALY estimates are
based on validated and appropriately weighted responses to
health-related, quality of life questionnaires such as the SF-36.
Methods
Searching
Systematic literature searches were conducted in the following
electronic databases: Medline (via PubMed), Embase,
CINAHL, Amed (Alternative and Allied Medicine Database,
British Library Medical Information Centre), The Cochrane
Library, NHS Economic Evaluation Database (via Cochrane)
and Health Technology Assessments (via Cochrane (all from
their inception to April 2005). The search terms used were as
follows: cost benefit*, cost util*, cost effectiv*, cost minimi*,
AND complementary medicine OR alternative medicine OR
chiropract* OR acupuncture OR homeopathy OR herbal
medicine OR phytotherapy OR osteopath* AND UK OR
Britain OR England OR Wales OR Scotland. In the case of the
PubMed search the third search term relating to UK origin was
restricted to the affiliation field. The same search was carried
out in October 2005 to identify any new studies published
since April 2005.
Selection
Only articles describing cost-effectiveness, cost-utility or
cost-benefit studies with prospectively collected data for two
or more interventions, of which one had to be a complementary
therapy, were included. Cost-minimization studies were
excluded because complementary therapies remain insuffi-
ciently tested within the NHS to warrant the assumption of
equal effectiveness with conventional treatments. Studies had
to be carried out in the UK.
Validity Assessment
Studies were considered valid if the data for health outcome
and cost were collected prospectively for two or more
interventions. Limitations to the completeness of cost data
and methodological problems regarding randomization, and
blinding are noted in the discussion.
Data Abstraction
All articles identified by the search strategy described above
were screened by the first author (P.C.) and all studies
appearing to meet the inclusion criteria at this stage were
retrieved and read in full. Data were extracted by the first
author (P.C.) and validated by the second (J.T.C.), with any
disagreements being settled by discussion between all three
authors.
Study Characteristics
Studies were grouped according to intervention and indication.
Results for the main outcome for health benefit and cost
analysis were extracted to a table and described narratively.
Quantitative Data Synthesis
Because of the expected heterogeneity of treatment interven-
tions and study populations no statistical combination of data
was planned.
Results
After removal of duplicates the initial search carried out in
April 2005 generated 453 references. Most failed to meet
several of the inclusion criteria, but only the first reason for
exclusion identified was recorded (Fig. 1). These were as
follows: not complementary medicine (n ¼ 255), not
UK-based (n ¼ 49), presented no primary cost data (n ¼ 89),
were reviews or commentaries (n ¼ 30), did not compare two
or more treatment options (n ¼ 9). The 11 remaining articles
were read in full and two (3,4) were excluded because they did
not have a control treatment. The remaining nine articles
(5–13) described five discrete studies, four of which were each
described by two publications addressing different aspects of
the same study.
The subsequent search carried out in October 2005 identified
33 additional articles of which 30 were excluded immediately
because they were reviews or commentaries (n¼ 18), were not
related to complementary medicine (n ¼ 6), included no cost
data (n ¼ 5) or were surveys (n ¼ 1). The other three articles
were retrieved and read in full. One was excluded because it
did not collect any primary cost data (14) and another because
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it did not test a complementary therapy (15). The third study
(16) was included meaning that six studies were included
overall.
Study Characteristics
The remaining 10 articles (5–13,16) described 6 discrete
studies, 4 of which were each described by two publications
addressing different aspects of the same study. Two studies
(5,6,16) were concerned with acupuncture and the other four
studies (7–13) with spinal manipulation. The included studies
are summarized in Table 1 and described below.
Acupuncture as an Adjunct to Usual Care for Headache
Vickers et al. (5,6) carried out a pragmatic randomized trial of
acupuncture for chronic headache (mainly migraine) in
primary care. Participants received usual care or usual care
plus individualized acupuncture. Mean scores calculated
from headache diaries fell by 34% in the acupuncture group
and 16% in controls between baseline and 12 months (P ¼
0.0002). A 35% reduction in headache score was predefined as
clinically relevant and this was achieved by 54% of
acupuncture patients and 32% of usual care patients, equiva-
lent to a number needed to treat 4.6 (95% CI 3.0–9.1). The
difference between treatments in days with headaches was
equivalent to 22 (8–38) additional headache free days per year
with acupuncture.
The associated cost-effectiveness study (6) calculated
treatment costs for the 12 months of the study. The cost of
prescription drugs was calculated for a subgroup of patients
(n ¼ 71) but this data were omitted from the analysis because
results were sensitive to the regression methods used.
Differences in medication cost between groups was small
(<£50 per patient) and tended to favor the acupuncture group.
Total costs during the 1 year period of the study were on
average higher with additional acupuncture (£403) than for
usual care (£217) mainly accounted for by the additional costs
of the acupuncture practitioners. Mean cost to the NHS per
patient excluding prescription costs was £290 in the acupunc-
ture group and £89 in the usual care group. Mean cost to
the patient was £114 in the acupuncture group and £129 in the
usual care group. Using the health-related quality of life
instrument SF-6D, the mean incremental health gain for
acupuncture above usual care was 0.021 QALY (P ¼ 0.02).
The mean incremental cost to the NHS excluding prescription
costs was £205 per patient and cost per QALY for acupuncture
in addition to usual care and adjusted for baseline differences
was £9180. Inclusion of productivity costs at £88 per day of
sick leave decreased incremental cost per QALY to £3263.
Assuming that there were lasting positive effects on quality of
life beyond the 12 month study period persisting for 2, 5 and 10
years reduced cost per QALY to £4730, £1807 and £801,
respectively. Using costs of private acupuncture increased cost
per QALY to £11 375 and acupuncture delivered by General
Practitioners (GP) seeing four patients per hour increased it to
£12333. Acupuncture delivered by trained physiotherapists
seeing three patients per hour reduced cost per QALY to
£5701.
Cost-Effectiveness of Manipulation Provided by
Chiropractors or the NHS for Low Back Pain
Meade et al. (7,8) published a clinical trial of 741 patients with
low back pain who were randomized to treatments provided by
either chiropractic or NHS hospital outpatient clinics. Treat-
ment was at the discretion of the therapists involved;
chiropractors used chiropractic manipulation in most patients,
hospital staff mostly used Maitland mobilization or manipula-
tion or both. Patients treated by chiropractors received 44%
more treatments than those treated in hospitals. Patients were
followed up for 2 years after treatment in the initial study and
at 3 years in the follow on. Oswestry questionnaires were
administered by post and the results reported initially (6) for
1 and 2 years were based on a much reduced dataset. We report
here the more complete data from the follow on (8). At
6 weeks, the difference in Oswestry score was not statistically
significant. At 6 and 12 months after treatment cessation, there
were small differences in Oswestry score between groups of
To April 2005 
Potentially relevant articles n=443
Not complementary medicine (n=255)
Not UK based (n=49)
No primary cost data (n=89)
Reviews/commentaries (n=30)
No control treatment (n=9) 
Total excluded (n=432)
Retrieved for detailed evaluation 
(n=11)
No control treatment (n=2)
Total excluded (n=2)
9 articles describing 5 unique 
studies1. 
April to October 2005. 
Potentially relevant articles (n=33)
Not complementary medicine (n=6)
No primary cost data (n=5)
Reviews/commentaries (n=18)
Surveys (n=1) 
Total excluded (n=30)
Articles retrieved for more detailed 
evaluation (n=3)
Not complementary medicine (n=1)
No primary cost data (n=1)
Total excluded (n=2)
Additional articles included (n=1)
10 articles describing 6 unique 
studies
Figure 1. Studies included and excluded from the systematic review.
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3.31 (0.51–6.11, P < 0.02, n ¼ 607) and 2.04 (0.71 to 4.79;
P ¼ NS, n ¼ 579), respectively, in favor of chiropractic. At
2 years, the difference had increased to 3.02 (0.08–5.96,
P < 0.05, n ¼ 541) and by 3 years it was 3.18 (0.16–6.20,
P < 0.05, n ¼ 529). Only direct costs of treatment provided
during the intervention period were considered; mean costs of
chiropractic and hospital-based treatments were £165 and
£111 per patient, respectively. The follow-on (7) showed that a
higher proportion of patients in the chiropractic group than the
hospital group sought further treatment of any kind for back
pain after completion of the trial treatment. Between 1 and
2 years after trial entry 42% of patients treated with
chiropractic and 31% of hospital-treated patients sought such
treatment but the additional cost of this further treatment was
not accounted for.
Comparison of Osteopathic Manipulation and
Chemonucleolysis in Lumbar Disc Herniation
Burton et al. (9) conducted a 12 month single-blind,
randomized trial comparing chemonucleolysis (injection of
the enzyme chymopapain) and osteopathic manipulation
delivered by a private practitioner in 40 patients with
symptomatic lumbar disc herniation resulting in sciatica.
Patients were recruited from the orthopaedic department of a
hospital in the north of England. The manipulative treatment
consisted of a number of 15 min treatment sessions over a
period not exceeding 12 weeks, with most sessions occurring
in the first 6 weeks. The mean number of manipulation
treatments received was 11 (range 6–18) at a cost of £20 per
session. The treatments followed a typical protocol for
osteopathic management of sciatica. Chemonucleolysis was
administered as an inpatient procedure under general anesthe-
sia and the cost including hospital and drug costs was £800.
Outcomes were assessed at baseline, 2 weeks, 6 weeks and
12 months. At 12 months, both treatment groups showed
significant improvements for mean scores for leg pain, back
pain and the Roland Disability Questionnaire with no
significant differences between groups. There was a statisti-
cally significant benefit of manipulation at 2 and 6 weeks for
back pain and at 2 weeks for mean disability score. The authors
considered only the direct costs of the interventions for the
30 patients with complete data at 12 months (15 in each group)
and the costs incurred for treating therapeutic failures (5 in the
manipulation group and 3 in the chemonucleolysis group);
they estimated that the saving per patient over 1 year
associated with manipulation would be £300.
Cost-Effectiveness of Manipulation in Addition to
Usual Care for Spinal Pain
Willliams (10,11) assessed the effectiveness and health care
costs of manipulation for subacute spinal pain in a primary
care-based osteopathy clinic accepting referals from 14
neighboring practices in Wales. It included 210 patients aged
16–65, with back or neck pain of 2–12 weeks duration who
were randomly assigned to usual GP care with or without three
sessions of osteopathic spinal manipulation. The primary
outcome measure was the Extended Aberdeen Spine Pain
Scale (EASPS) which, at 2 months, showed a significantly
greater improvement in the osteopathy group than in the usual
care group (95% CI 0.7–9.8). This difference was no longer
significant at 6 months (95% CI 1.5 to 10.4).
Data on health care use were collected for 6 months
preceeding and 6 months following randomization and costs
were calculated for primary care consultations, investigations,
prescribing and referrals. Mean health care costs attributed to
spinal pain for the 6 months of the trial were £129 (SD £283) in
the osteopathy group and £64 (SD £90) in the usual care group,
a significant difference of £65 (95% CI £32–£155). Mean total
health care costs in the same period were £328 (£564) in the
osteopathy group and £307 (£687) in the usual care group, a
non-significant difference of £22 (95% CI £159 to £142).
The cost-utility analysis found that differences between
groups in mean QALY calculated from EuroQol EQ-5D data
favored osteopathy but were not statistically significant when
using data from only patients with complete data (0.006, 95%
CL 0.033 to 0.046, n ¼ 108), using estimated values for
missing EQ-5D data (0.018, 95% CL 0.017 to 0.052,
n ¼ 146) or patients with estimated EQ-5D values and
complete cost data (0.025, 95% CL0.012 to 0.060, n¼ 136).
Based on the third, and most optimistic of these, mean QALY
and total costs were 0.031 and £215 with usual GP care, and
0.056 and £303 with additional osteopathy. Cost per QALY
gain in the osteopathy group was estimated as £3560. The
median bootstrap cost-utility estimate was £3760 per QALY
gained (80% CL £542–£77 100). A sensitivity analysis
omitting data from three outliers (one in GP group, two in
osteopathy group) gave a bootstrapped estimate of £1390 for
cost per QALY (upper 80% CL £13 400). When only
spine-related costs were considered, the median bootstrapped
estimate was £2870 per QALY gained (80% CL £998–
£36 500). These findings suggest an increase in mean QALY
and a small increase in cost associated with the addition of
osteopathy to usual GP care but the estimates for cost per
QALY are subject to a high level of random error. The
cost-utility plot does not suggest that incremental increases in
spending on osteopathy are associated with incremental gains
in QALY.
The UK Beam Trial: Manipulation and Exercise for
Low Back Pain
In the UK Beam trial (12,13) patients with low back pain (n ¼
1334) were randomized to GP best care (emphasis on normal
activity and avoiding rest), GP care plus manipulation
(delivered by chiropractors, osteopaths or physiotherapists),
GP care plus exercise classes (delivered by a physiotherapist)
or GP care plus manipulation followed by exercise classes.
Patients allocated to manipulation were further randomized
between manipulation in private premises and in NHS
premises to give a 3 · 2 factorial design. Manipulation
comprised a package of techniques agreed by a panel of UK
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chiropactors, osteopaths and physiotherapists. Outcomes were
measured at baseline, 3 months and 12 months.
The main outcome measure was the Roland Morris disability
questionnaire in which changes of 2.5 are usually considered
clinically important . Compared to GP care alone, the exercise
group showed statistically significant improvement at 3 months
(1.4, 95% CL 0.6–2.1) but not at 12 months. Manipulation was
significantly better than GP care at 3 months (1.6, 0.8–2.3) and
12 months (1.0, 0.2–1.8). Manipulation followed by exercise
was significantly better than GP care at 3 months (1.9, 1.2–2.6)
and 12 months (1.3, 0.5–2.1). The authors describe the effect
sizes as small to moderate. There was no significant difference
on any measure between manipulation delivered in private or
NHS premises.
The cost-utility analysis (13) was based on participants with
sufficient cost data (n ¼ 1287) and assumed the lower costs of
manipulation delivered in NHS premises. Based on EQ-5D
data, the mean (SD) QALY was 0.618 (0.232) for best care,
0.635 (0.245) for best care plus exercise, 0.659 (0.241) for best
care plus manipulation and 0.651 (0.237) for best care plus
combined treatment. Mean incremental QALY generated
per participant relative to best care was therefore 0.041
(95% credibility interval 0.016–0.066) for manipulation, 0.017
(0.017 to 0.051) for exercise and 0.033 (0.001 to 0.067) for
combined treatment. The mean incremental treatment cost
above best care was £195 (£85–£308) for manipulation, £140
(£3–£278) for exercise and £125 (£21–£228) for combined
treatment. The lower incremental cost for the combined
additional treatment resulted from lower subsequent hospital
costs. The cost-utility analysis shows that cost per QALY for
combined treatment is £3800. Exercise alone was more
expensive and achieved less, i.e. was ‘dominated’ by
combined treatment and was excluded as a treatment option.
For manipulation alone, cost per QALY was £4800 relative to
best care and £8700 relative to best care plus combined
treatment. Several sensitivity analyses were performed.
Excluding outliers whose health care costs exceeded £2000
(best care, n ¼ 9; exercise, n ¼ 16; manipulation, n ¼ 16;
combined treatment, n ¼ 10) caused manipulation to achieve
dominance over both exercise and combined treatment with a
cost per additional QALY of £3000. Cost per QALY relative to
best care was £6600 for combined treatment and £8700 for
manipulation when private costs were substituted for the
manipulation carried out in private premises and were £8600
for combined treatment and £10 600 for manipulation when
private costs were substituted for all manipulation given in the
trial. The authors note that shortage of trained manipulators
within the NHS means that in the short-term at least,
manipulation would have to be bought in from the private
sector.
Traditional Acupuncture in Low Back Pain
The most recent study (16) tested the hypothesis that patients
with persistent non-specific low back pain, offered traditional
acupuncture as an adjunct to conventional primary care, would
gain more long-term relief from pain than those offered
conventional care alone for equal or less cost. The study was
carried out in three non-NHS acupuncture clinics taking
referals from 39 GPs in 16 practices in York. Patients (n ¼
241) aged 18–65 years with non-specific low back pain of
4–52 weeks duration, assessed as suitable for primary care
management by their GP were randomized to the offer of
acupuncture or usual care with a 2:1 allocation ratio. In
addition to usual care as provided at the discretion of their GP,
patients in the acupuncture group were offered up to 10
individualized treatment sessions with one of six non-NHS
acupuncturists and adjunctive treatments including moxa,
cupping, acupressure, massage, Chinese herbs and advice on
diet, rest and exercise. Usual care entailed a mixture of
physiotherapy, medication and recommended back exercises.
The primary outcome measure was the SF-36 Bodily Pain
dimension assessed at baseline, 3, 12 and 24 months.
Cost-utility analysis was carried out at 24 months using
quality of life assessments from both the EuroQuol-5D and a
measure derived from the SF-36 (SF-6D).
All 159 patients randomized to acupuncture took up the offer
and of these 9 did not receive any acupuncture treatment.
Patients received an average of eight acupuncture treatments,
mostly within the first 3 months of the study. Changes from
baseline on the SF-36 Bodily Pain dimension were not
statistically different at 3 months (95% CI 1.5 to 11.6) or
12 months (95% CI 1.3 to 12.5) and were significantly
different at 24 months with a treatment effect of 8.0 points
(95% CI 0.7–15.3). An analysis of heterogeneity in the main
outcome found that 35% of the variability was associated with
the acupuncturist at 12 months but with no significant
difference between the six practitioners. At 24 months the
variability was 2%. The difference in treatment effect at 24
months did not significantly differ between subacute patients
(4–12 weeks of back pain) and chronic patients (12–48 weeks).
At baseline, 50.3% of acupuncture patients and 37.5% of usual
care patients expected their back pain to be better in 6 months
time and there was a non-significant interaction such that
acupuncture patients had their initial optimism reinforced.
Among the secondary outcome measures there was a
significant difference favoring acupuncture on the McGill
Present Pain Intensity scale (PPI) at 3 months (P ¼ 0.02) but
not at 12 or 24 months. There were no significant differences
between groups on the other seven dimensions of the SF-36 or
on the Oswestry Low Back Pain Disability Questionaire
(ODI). At 24 months, the acupuncture group reported
significantly more months free of pain in the preceeding 12
months (P ¼ 0.03) and a lower proportion (40 versus 60%)
reported using medication for back pain in the previous 4
weeks (P ¼ 0.03). By 24 months more acupuncture patients
than usual care patients reported being ‘much less’ or ‘less’
worried about their back pain and were more likely to attribute
their improvements to the treatment received (P< 0.001). At 3
months more acupuncture patients reported being very
satisfied with their treatment (P ¼ 0.01) and their overall
care (P ¼ 0.04).
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Cost-effectiveness was calculated from both NHS and
societal perspectives including NHS costs, private treatment
costs and the cost of lost productivity. The total mean NHS
costs for back pain were £471 for acupuncture and £332 for the
usual care group a difference of £139 (P < 0.05, 95% CI
£23–£255). The mean cost of the study acupuncture was £214.
This was offset by higher costs in the control group for
hospitalizations, GP, outpatient and other health care visits.
Curiously, the mean cost of medication for back pain was over
twice as high in the acupuncture group (£34 SD £114) as in the
control group (£16 SD £27).
Total health care costs for back pain including private
treatment were £525 for acupuncture and £367 for usual care, a
statistically non-significant difference of £158 (95% CI £28
to £320). The total social costs including estimates of lost
productivity for time-off work were lower for the acupuncture
group (£2135) than the usual care group (£2470), but not
significantly so.
There were no significant intergroup differences in incre-
mental quality of life scores on the SF-6D scores at 3, 12 or 24
months or on the EQ-5D at 12 and 24 months. The EQ-5D data
favored acupuncture at 3 months (P< 0.05). Imputing missing
values in the EQ-5D data from regression analysis of the SF-36
data did not change this pattern of results, but an area under the
curve (AUC) analysis found a statistical difference favoring
acupuncture at 24 months (P < 0.05).
At 24 months the estimated incremental cost per QALY for
acupuncture relative to usual care was £4241 (95% CI
£191–£28 026) using the SF-6D measure and £3598
(£189–£22 035) using the EQ-5D data. Cost per QALY was
estimated using the AUC data available for quality of life and
NHS treatment costs for acupuncture patients (n ¼ 78) and
usual care patients (n ¼ 44).
Quantitative Data Synthesis
None planned or executed.
Discussion
Our search located only six prospective, controlled, cost-
effectiveness studies of complementary therapies conducted in
the UK. The studies are restricted to two modalities and two
medical conditions within the broad spectrum of complemen-
tary and alternative medicine and many indications for which
it is used: spinal manipulation for back pain, acupuncture for
headache and acupuncture for back pain. Given the paucity of
good data, it is premature to draw firm conclusions about the
cost-effectiveness of using any complementary therapy in the
UK health system. The general question ‘is complementary
medicine cost-effective?’ is of course unanswerable. Cost-
effectiveness can only be assessed for a specific complemen-
tary therapy in a particular indication within a particular health
care system.
Of the six studies meeting our inclusion criteria, four
(4,5,10,11–13,16) made useful comparisons between the
complementary therapy and usual care and also estimated
cost per QALY. The other two studies did not make such
useful comparisons. Meade et al. (6,7) compared the
cost-effectiveness of different forms of spinal manipulation
carried out in private and NHS settings and Burton et al. (9)
compared osteopathic manipulation with chemonucleolysis, a
procedure used only when other standard treatments have
failed.
All four studies comparing complementary therapy with
usual care indicate that use of the complementary therapy in
addition to, or as an alternative to, usual or conventional
treatment represents an increase in total health care costs.
There is presently no direct evidence from prospectively
conducted and controlled studies that the use of any comple-
mentary medicine modality used in addition to or instead of
routine care, reduces costs in the UK health care system.
In the case of spinal manipulation, the health benefits
observed in these studies were small to moderate and of
questionable clinical significance. The effectiveness of spinal
manipulation in back pain remains controversial and the most
rigorous RCTs fail to demonstrate it’s usefulness (17,18).
Similarly, the efficacy of acupuncture in the indications
studied remains uncertain. In the trial comparing adjunctive
acupuncture with usual care for chronic back pain (16) the
difference between groups on the main clinical outcome
measure did not reach statistical significance until the 24
month measurement. Data from the most recent systematic
reviews of acupuncture for pain appear to indicate that effect
sizes diminish as clinical trials become more rigorous and
include larger samples (19). Large-scale trials conducted in
Germany and due to report their findings shortly, are expected
to show similar effectiveness for real and sham acupuncture in
pain (19). More specifically, real and sham acupuncture appear
to be equally effective in treating migraine (20).
Previous decisions taken by the National Institute for
Clinical Excellence (NICE) (21), the body which advises
government and the NHS on the cost-effectiveness of new
treatments, imply an upper limit above those for acupuncture
and manipulation in this review here at £10 000 per QALY or
considerably less. However, it may be misleading to compare
these pragmatic studies with studies of other treatments
accepted by for use in the NHS. The absence of blinding and
control treatments in these trials and the use of subjective
quality of life measures upon which the cost-effectiveness
analyses are based, may have enhanced non-specific treatment
effects, particularly placebo effects attributable to differential
expectations of patients randomized to different treatments. It
will be argued that this does not matter because cost-
effectiveness analyses should take such effects into account
by reflecting how treatments are likely to be delivered in ‘real
life’. However, such effects may not operate in a situation
where the complementary therapy is offered routinely, is not
offered in the novel situation of a clinical trial, or where
disappointment associated with allocation to usual care is not
generated. The use of pragmatic cost-effectiveness studies is
justified in treatments where appropriately blinded and
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sham-controlled randomized clinical trials have already
demonstrated efficacy in the indication concerned, but this is
not the case for the interventions included in this review.
The picture emerging from the most rigorous cost-
effectiveness studies of complementary medicine in the UK
is a rather consistent one. First, their use represents an
additional cost to the NHS. Second, estimates of cost-
effectiveness based on data from clinical trials without sham
controls compare favorably with other treatments approved for
use in the NHS. Third, the specific treatment effects of the
complementary therapies for the indications in question
remains uncertain. We therefore strongly suspect that such
studies may be estimating the cost-effectiveness of non-
specific treatment effects. We recommend that future cost-
effectiveness studies of complementary therapies include a
sham treatment arm.
Conclusions
There are presently very few prospective, controlled studies of
the cost-effectiveness of complementary therapies in the UK
and those published are confined to two modalities: spinal
manipulation and acupuncture. The evidence that is available
suggests that the use of these complementary therapies
represents an additional cost and there is no evidence that
their use leads to savings. Cost-utility analyses included in
these studies compare favorably in terms of cost per QALY
with other treatments accepted for use in the NHS, but because
the specific efficacy of the complementary therapies for
these indications remains uncertain, and the studies did not
include sham controls, the estimates obtained may represent
the cost-effectiveness non-specific effects associated with the
complementary therapies.
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